JMP Securities Upgrades Vertex Pharmaceuticals Incorporated to Market Outperform

Brokerage firm JMP Securities Upgrades its rating on Vertex Pharmaceuticals Incorporated(VRTX). The shares have been rated Market Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by the stock financial advisor at JMP Securities was issued on Mar 17, 2017 in a research report to their Investors and Clients.

Vertex Pharmaceuticals Incorporated (VRTX) made into the market gainers list on Wednesdays trading session with the shares advancing 0.60% or 0.54 points. Due to strong positive momentum, the stock ended at $90.04, which is also near the day’s high of $90.25. The stock began the session at $89.95 and the volume stood at 13,37,153 shares. The 52-week high of the shares is $103.73 and the 52 week low is $71.46. The company has a current market capitalization of $22,369 M and it has 24,84,38,130 shares in outstanding.

Vertex Pharmaceuticals Incorporated(VRTX) last announced its earnings results on Jan 25, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $458.706M. Analysts had an estimated revenue of $453.320M. Earnings per share were $0.35. Analysts had estimated an EPS of $0.29.

Several Insider Transactions has been reported to the SEC. On Mar 2, 2017, Ian F Smith (EVP, CFO & COO) sold 3,842 shares at $90.00 per share price.Also, On Feb 15, 2017, Stuart A Arbuckle (EVP\Chief Commercial Officer) sold 3,792 shares at $88.39 per share price.On Feb 15, 2017, David Altshuler (EVP, Global Research and CSO) sold 6,403 shares at $87.68 per share price, according to the Form-4 filing with the securities and exchange commission.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Add Comment